Article

CML: Initiating, Switching, and Monitoring Therapy

This Webcast activity concerns the various aspects of managing therapy for patients with CML.

Credits: 1.50

Fee: None

Expires: October 30, 2010

Multimedia: Webcast

This Webcast activity concerns the various aspects of managing therapy for patients with CML. After completing the activity, oncology nurses should be able to review the safety and efficacy of tyrosine kinase inhibitors in treating patients with CML based on results from recent clinical trials, discuss disease monitoring to determine treatment response and when switching therapy is necessary, describe the standard of care in first-line therapy and ongoing investigational trials in patients initiating therapy, and outline a treatment plan for the management of patients with advanced-phase CML and imatinib resistant/intolerant CML.

Click here to access this third-party website.

Related Videos
Skin of Color Savvy: News Update—Addressing Disparities, Black History Month, & Mentorship Opportunities
Medical Sisterhood: James Del Rosso, DO
5 experts in this video
3 experts are featured in this series.
3 experts are featured in this series.
5 experts in this video
Understanding Angioedema in Urticaria, with Jonathan Bernstein, MD
© 2025 MJH Life Sciences

All rights reserved.